The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity

Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have been used to identify cancer patients at increased cardiovascular risk. The primary aim of our study was to evaluate the usefulness of the new cardiovascular risk assessment model proposed by the Cardio‐Oncology Study Group of the Heart Failure Association (HFA) of the ESC in collaboration with the International Cardio‐Oncology Society (ICOS) to stratify the cardiovascular risk in CML patients, compared with SCORE risk charts. The secondary aim was to establish the incidence of adverse arterial events (AEs) in patients with CML treated with TKIs and the influence of preventive treatment with aspirin.

[1]  I. Porto,et al.  Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice. , 2021, International journal of cardiology.

[2]  I. V. Van Gelder,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2021, European heart journal.

[3]  R. Foà,et al.  Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib , 2021, Annals of Hematology.

[4]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[5]  A. Russo,et al.  Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience , 2020, Oncology.

[6]  N. Brunetti,et al.  Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib , 2020, Heart Failure Reviews.

[7]  F. Crea,et al.  Commentary: The new ESC guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, International journal of cardiology.

[8]  Marco Valgimigli,et al.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.

[9]  R. Foà,et al.  Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart , 2019, Hematological oncology.

[10]  Martin C. Müller,et al.  Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. , 2018, Blood.

[11]  R. Foà,et al.  Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: Identification of risk factors and the role of prophylaxis , 2018, American journal of hematology.

[12]  J. Lipton,et al.  Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long‐term Follow‐up , 2017, Clinical lymphoma, myeloma & leukemia.

[13]  M. Baccarani,et al.  Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion , 2017, Annals of Hematology.

[14]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, European heart journal cardiovascular Imaging.

[15]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[16]  Paul W Dickman,et al.  Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Touyz,et al.  Vascular Complications of Cancer Chemotherapy , 2016, The Canadian journal of cardiology.

[18]  D. Steensma,et al.  Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. , 2015, Journal of the American College of Cardiology.

[19]  G. Novo,et al.  Preclinical carotid atherosclerosis enhances the global cardiovascular risk and increases the rate of cerebro- and cardiovascular events in a five-year follow-up. , 2010, Atherosclerosis.

[20]  G. Boysen.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[21]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[22]  J. Voigt,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[23]  A. Hinman.  Disease prevention in clinical practice. , 1976, New York state journal of medicine.